Skip to content
PolyPid Ltd.  logo — Controlled, extended-release, local delivery of medication a...

PolyPid Ltd.

Controlled, extended-release, local delivery of medication at effective release rates over predetermined durations.

Founded 2008 Israel Israel 66 employees Post-IPO Equity Total: $139.80M Biopharma, Biotechnology +2

General Information

Company Name PolyPid Ltd.
Founded Year 2008
Location Israel Israel
Founders / Decision Makers
Team member
Employees 66
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with PolyPid Ltd. . To contact PolyPid Ltd. , visit polypid.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does PolyPid Ltd. compare?

A PDF of PolyPid Ltd. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting PolyPid Ltd. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About PolyPid Ltd.

PolyPid Ltd. is a global clinical-stage bio-pharmaceutical company with a focus on developing, manufacturing, and commercializing novel therapies for surgical outcomes. The company's PLEX (Polymer-Lipid Encapsulation matriX) technology is designed to provide controlled and continuous delivery of medications at surgical sites, targeting localized medical conditions such as infection, pain, inflammation, and cancer. Their innovative approach aims to improve patient outcomes, particularly in addressing Surgical Site Infections (SSIs), a prevalent type of Healthcare Acquired Infections (HAIs). With a commitment to reducing overall surgical infection rates, including those due to antibiotic-resistant bacteria, PolyPid's efforts align with addressing public health challenges as identified by the FDA. Founded in 2008 and headquartered in Israel, the company received a significant $16.20MPost-IPO Equity investment on 04 January 2024 from DAFNA Capital Management, LLC and Rosalind Capital Partners. Trading under the symbol PYPD on NASDAQ, PolyPid is positioned to make a significant impact in the biopharma, biotechnology, health care, and pharmaceutical industries.

Business keywords: bio-pharmaceutical, surgical therapies, drug delivery, local medication, Polymer-Lipid Encapsulation matriX, surgical site infections, antibiotic resistance, clinical-stage, drug development, global healthcare, FDA-approved treatments

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $16.20M 2
DAFNA Capital Management, LLC, Rosalind Capital Partners
04 Jan 2024
Post IPO Debt $15.00M 1
Kreos Capital
06 Apr 2022
Series E $65.32M 1
Apple Core Holdings
31 Oct 2018
Series D $22.00M 3
AUM Ventures, Shavit Capital +1
23 Feb 2016
Series C $8.26M 2
Financière Saint-James, Guibor
06 Nov 2015
Series B $10.86M -
30 Jun 2014
Series A $2.16M -
08 Dec 2011

PolyPid Ltd. Alternatives & Competitors

View All Alternatives
PolyPid Ltd. vs

Our Mission: Answering the call to action to fight antibiotic resistance

Series B
7 employees
Biopharma, Biotechnology
PolyPid Ltd. vs
Micreos
Micreos Switzerland

Micreos is a biotech company focused on discovering and developing recombinant technology

Venture round
21 employees
Biotechnology, Design
PolyPid Ltd. vs

Bringing life-changing therapeutics to China and the world.

Post-IPO Equity
44 employees
Biotechnology, Pharmaceutical

FAQ About PolyPid Ltd.

Controlled, extended-release, local delivery of medication at effective release rates over predetermined durations.
PolyPid Ltd. was founded in 2008.
PolyPid Ltd. is headquartered in Israel.
PolyPid Ltd. operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on bio-pharmaceutical, surgical therapies, drug delivery and local medication.
PolyPid Ltd. has approximately 66 employees.
PolyPid Ltd. has completed 7 funding rounds, raising a total of $139.80M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to PolyPid Ltd. include Allecra Therapeutics, Micreos , CASI Pharmaceuticals, Inc., Arpida, Microbion Corporation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
PolyPid Ltd. and Allecra Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for PolyPid Ltd. , https://www.bouncewatch.com/company/polypid-ltd, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout